Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Lists
Only you see this
Abstract
Durvalumab plus olaparib increased immune cell infiltration of TME with clinical benefit in some patients with leiomyosarcoma. Baseline M1-macrophage and B-cell activity may identify patients with leiomyosarcoma with favorable outcomes on immunotherapy and should be further evaluated.
BibTeX
@inproceedings{salawu2023safety,
author = {Abdulazeez Salawu and Ben X. Wang and Ming Han and Caryn Geady and Alya Heirali and Hal K. Berman and Thomas D. Pfister and Alberto Hernando‐Calvo and Esmail Mutahar Al-Ezzi and Lee-Anne Stayner and Abha A. Gupta and Olubukola Ayodele and Bernard Lam and Aaron R. Hansen and Anna Spreafico and Philippe L. Bédard and Marcus O. Butler and Lisa Avery and Bryan Coburn and Benjamin Haibe‐Kains and Lillian L. Siu and Albiruni R. Abdul Razak},
title = {{Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.}},
booktitle = {Clinical},
year = {2023},
doi = {10.1158/1078-0432.ccr-23-1137},
}Loading related content...